drugset / Trial / NCT00303290

PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML

NCT00303290

NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to see if a new interferon which is given only once a week with ARA-C works as well as standard interferon and low dose ARA-C. The safety of this treatment will also be studied.

Timeline

Start
2000-01
Primary completion
2014-11
Completion
2014-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Cytarabine Small molecule 10 mg Subcutaneous
Subject Peginterferon alfa-2b Protein / enzyme biologic 4.5 ug/kg